Fantastic Frogs and Where to Use Them: Unveiling the Hidden Cinobufagin’s Promise in Combating Lung Cancer Development and Progression Through a Systematic Review of Preclinical Evidence DOI Open Access
Sandra Maria Barbalho, Karina Torres Pomini,

Enzo Pereira de Lima

и другие.

Cancers, Год журнала: 2024, Номер 16(22), С. 3758 - 3758

Опубликована: Ноя. 7, 2024

Cinobufagin (CB), a bufadienolide, has shown promising potential as an anticancer agent, particularly in combating lung cancer. This systematic review synthesizes preclinical evidence on CB's effects against cancer, focusing its mechanisms of action, efficacy, and clinical implications. We analyzed data from various studies involving both vitro cell line models vivo animal models. The reviewed indicate that CB effectively reduces viability, induces apoptosis, inhibits proliferation, migration, invasion across multiple cancer lines xenograft Specifically, was found to decrease viability increase apoptosis cells by modulating key molecular pathways, including Bcl-2, Bax, cleaved caspases, caveolin-1, FLOT2, Akt, STAT3, FOXO1. In further demonstrated significant inhibition tumor growth with minimal toxicity. However, limitations include reliance models, which may not fully represent dynamics, lack long-term safety data. also vary their methodologies accurately encompass all subtypes or predict human responses. Despite these limitations, ability target specific pathways results suggest it could be valuable addition treatment strategies. Our suggests trials validate efficacy humans. Future research should explore combination therapies optimize delivery methods enhance outcomes.

Язык: Английский

Unveiling the multifaceted roles of long non-coding RNA CTBP1-DT in human diseases: Special attention to its microprotein-encoding potential DOI

Jingjie Yang

Pathology - Research and Practice, Год журнала: 2025, Номер 268, С. 155870 - 155870

Опубликована: Фев. 26, 2025

Язык: Английский

Процитировано

0
A Comparison of Treatment With Skin Graft or Secondary Healing for Nasal Wound Defects After Tumor Excision: A Randomized Study DOI Creative Commons
Sinan Doğan, Ingrid Steinvall, Jean‐Michel Halimi

и другие.

Plastic & Reconstructive Surgery Global Open, Год журнала: 2025, Номер 13(3), С. e6620 - e6620

Опубликована: Март 1, 2025

A full-thickness skin graft is a commonly used method for repairing smaller nasal defects. Secondary healing simple alternative with many advantages, although it associated long duration of healing. The aim was to compare the short- and long-term results transplantation or secondary small wound defects after tumor excision. Adult patients admitted resection were randomized treatment either intent. Healing complications assessed at 1 4 weeks. Scar quality patient observer scar assessment scale (POSAS) 6 months postoperatively. Twenty-six included. Three healed within week in group, whereas none had group (SHG). time (median [interquartile range]) 35.0 (28.0-41.0) days 28.0 (12.0-48.0) SHG respectively (P = 0.47). Patient-POSAS scores reported better all items (pain, itching, color, stiffness, thickness, irregularity), not significantly. Observer-POSAS vascularity, pigmentation, relief 0.003, 0.007, 0.002, 0.01, respectively). did differ between 2 groups. cosmetic outcome showed promising SHG, suggesting that allowing superficial, surgery may be beneficial. However, strength this conclusion hampered by study group.

Язык: Английский

Процитировано

0
Exploring cell death pathways in oral cancer: mechanisms, therapeutic strategies, and future perspectives DOI Creative Commons

Chenyi Zhao

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Март 26, 2025

Oral squamous cell carcinoma (OSCC) represents a significant global health challenge, characterized by aggressive progression and poor therapeutic response despite advances in treatment modalities. This review provides comprehensive analysis of diverse death mechanisms OSCC, encompassing traditional pathways (apoptosis, autophagy, necrosis), newly (ferroptosis, pyroptosis, necroptosis), emerging (cuproptosis, anoikis, parthanatos, entosis). By examining the molecular basis these pathways, particularly crucial roles p53 signaling miRNA regulation, we highlight how their dysregulation contributes to resistance tumor progression. The synthesizes recent evidence demonstrating complex interplay between ten distinct impact on microenvironment immune response. We evaluate innovative approaches that target including novel small molecules, combination strategies, immunomodulatory treatments exploit specific enhance efficacy. Special attention is given personalized medicine strategies consider individual characteristics pathway profiles. integrating current challenges with future research directions, this framework for developing more effective can leverage multiple overcome therapy improve outcomes oral cancer patients.

Язык: Английский

Процитировано

0
AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B‐Associated DNA Repair in Bladder Cancer DOI
Zehua Liu, Bolin Jia, Zhao Zhai

и другие.

The FASEB Journal, Год журнала: 2025, Номер 39(10)

Опубликована: Май 19, 2025

ABSTRACT The combination of gemcitabine and cisplatin serves as a cornerstone in bladder cancer (BC) treatment, yet chemotherapy resistance continues to pose significant challenge. This study utilizes novel BC organoid model integrated with drug sensitivity assays uncover the mechanisms underlying identify potential therapeutic targets. Our findings reveal that AP1M2 expression is markedly upregulated gemcitabine‐ cisplatin‐resistant cells tissues. Elevated levels contribute enhanced tumor cell proliferation by facilitating DNA damage response increasing RAD54B expression. Mechanistically, interacts RNA‐binding protein PUM1 stabilize mRNA, thereby supporting repair survival under chemotherapeutic stress. Notably, inhibition AP1M2/PUM1‐mediated sensitized xenografts gemcitabine‐cisplatin treatment vivo. These unveil mechanism highlight AP1M2/PUM1/RAD54B pathway promising target counter enhance outcomes.

Язык: Английский

Процитировано

0
Fantastic Frogs and Where to Use Them: Unveiling the Hidden Cinobufagin’s Promise in Combating Lung Cancer Development and Progression Through a Systematic Review of Preclinical Evidence DOI Open Access
Sandra Maria Barbalho, Karina Torres Pomini,

Enzo Pereira de Lima

и другие.

Cancers, Год журнала: 2024, Номер 16(22), С. 3758 - 3758

Опубликована: Ноя. 7, 2024

Cinobufagin (CB), a bufadienolide, has shown promising potential as an anticancer agent, particularly in combating lung cancer. This systematic review synthesizes preclinical evidence on CB's effects against cancer, focusing its mechanisms of action, efficacy, and clinical implications. We analyzed data from various studies involving both vitro cell line models vivo animal models. The reviewed indicate that CB effectively reduces viability, induces apoptosis, inhibits proliferation, migration, invasion across multiple cancer lines xenograft Specifically, was found to decrease viability increase apoptosis cells by modulating key molecular pathways, including Bcl-2, Bax, cleaved caspases, caveolin-1, FLOT2, Akt, STAT3, FOXO1. In further demonstrated significant inhibition tumor growth with minimal toxicity. However, limitations include reliance models, which may not fully represent dynamics, lack long-term safety data. also vary their methodologies accurately encompass all subtypes or predict human responses. Despite these limitations, ability target specific pathways results suggest it could be valuable addition treatment strategies. Our suggests trials validate efficacy humans. Future research should explore combination therapies optimize delivery methods enhance outcomes.

Язык: Английский

Процитировано

3